A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Trial Details

NCT ID

NCT04570423

Phase

PHASE2

Sponsor

Spectrum Pharmaceuticals, Inc

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• Eflapegrastim
• Chemotherapy

Locations (sample)

• Valhalla, New York, United States|41.07482,-73.77513
• Charlotte, North Carolina, United States|35.22709,-80.84313
• Charlotte, North Carolina, United States|35.22709,-80.84313
• Cleveland, Ohio, United States|41.4995,-81.69541
• Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

• Participant must have a pathologic/histologic confirmed newly diagnosed/relapsed/recurrent solid tumor or lymphoma without bone marrow involvement.
• Participant must be a candidate to receive myelosuppressive chemotherapy, with a febrile neutropenia rate of at least 20% as outlined in the Nation…
• Participant has adequate hematological, renal, and hepatic function.
• Participant must have an echocardiogram (ECHO) or multigated acquisition (MUGA) within 14 days of Screening if receiving a cardiotoxic therapy and …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.